Inside Althexis

Athens, February 10, 2026 – ALTHEXIS, a company operating in the field of Digital Health, announced the completion of a €400,000 funding round. The round was led by Corallia Ventures, with significant participation from Pablo Pinedo David and the Hellenic Business Angels Network (HeBAN), which actively supports startups in their early stages by providing capital, expertise, and access to international networks.

The investment will accelerate the commercial expansion of the Skincare Suite platform, a data-driven sales optimization solution. The solution was designed to help brick-and-mortar pharmacies compete with e-commerce by significantly enhancing personalized sales, enabling them to increase their skincare product revenues by up to 25%, according to pilot implementation results.

Revenue growth and in-store experience upgrade

ALTHEXIS helps brick-and-mortar pharmacies address the critical challenge of differentiation from competition and boosting sales of high-margin products. The Skincare Suite platform uses multispectral imaging technology and Generative Artificial Intelligence (Generative AI) to accurately analyze key skin parameters—such as oiliness, hydration, texture, discolorations, and sebum levels. By combining this data with the customer’s profile and the pharmacy’s available inventory, the platform instantly generates personalized and scientifically documented skincare routines, enhancing trust and improving in-store customer conversion rates.

Added value for pharmacies and skincare product manufacturers

Through a session lasting just 3 minutes, ALTHEXIS transforms pharmacy staff into trusted skincare product advisors who leverage data to recommend personalized solutions to customers. In this way, the Althexis Skincare Suite creates added value for both pharmacies and skincare product manufacturers.

On the one hand, pharmacies benefit from increased sales, customer retention through personalized follow-ups, and the strengthening of long-term trust. On the other hand, product manufacturers gain access to a Business Intelligence platform with anonymized data, providing detailed market analyses, demographic insights, and targeted opportunities for sponsored product placements (sponsored slots) on the ALTHEXIS platform.

Use of funds and investment strategy

The funding will accelerate penetration of the Greek market during the validation phase and contribute to the company’s global expansion. ALTHEXIS is already establishing partnerships with major pharmacy chains and cosmetics manufacturers, as it plans to enter key European markets such as Italy and Spain starting in 2027. Its goal is to become the leading technology provider for science-based sales growth in brick-and-mortar skincare retail.

Commenting on the announcement, Antonis Nikitakis, Co-Founder and CEO of ALTHEXIS, stated:

“This investment confirms the critical transformation taking place in pharmacies. Over the past decade, pharmacies have aesthetically evolved, transforming sterile spaces into attractive experiential destinations. However, the core challenge remained: skincare product recommendations are still based on assumptions or require specialized staff. With Skincare Suite, we bring science directly to the pharmacy counter. We empower every employee to deliver scientific advice within minutes, building a relationship of trust that keeps brick-and-mortar pharmacies competitive against e-commerce.”

Dr. Jorge-A. Sanchez-P., Partner at Corallia Ventures TT, stated:

“ALTHEXIS is an excellent example of how deep scientific expertise can be translated into a scalable and commercially strong digital health product. We were impressed not only by the technology, but also by the team’s understanding of the need for personalization within the pharmacy channel. We are excited to support the company as it expands internationally.”

Pablo Pinedo David, Angel Investor, stated:

“What convinced me about ALTHEXIS is its position within the value chain. It transforms a traditionally non-optimized environment into a data-driven growth engine, while preserving the human trust that makes pharmacies stand out.”

Dimitris Tsigos, Co-Founder of HeBAN – Hellenic Business Angels Network, noted:

“At the Hellenic Business Angels Network, we are excited to participate in Althexis’ funding round. We believe the company has strong growth prospects and that the meaningful and productive utilization of Artificial Intelligence in the healthcare sector offers opportunities for rapid expansion in the international market. HeBAN, which now brings together more than 100 angel investors, is committed to prioritizing ventures that have emerged from the Greek research and innovation ecosystem, which makes our satisfaction with this particular investment even greater.”

About ALTHEXIS

Althexis P.C. is a Greek digital health startup that connects advanced dermatoscopy with sales optimization through AI. By combining multispectral imaging with analytical data, it transforms clinical skin analysis into personalized product recommendations. More at: https://althexis.com

About Corallia Ventures TT

Corallia Ventures is a venture capital fund focusing on early-stage deep-tech startups with global ambitions. It invests in Health technologies, Artificial Intelligence, and more. Corallia Ventures TT is co-financed by the Hellenic Development Bank (HDB). More at: https://www.coralliaventures.vc

Contact

ALTHEXIS
[email protected]
Thessalonikis 75 & Florinis, 18345 Moschato, Attica, Greece

Corallia Ventures
[email protected]
262 Kifisias Ave., 14562 Kifisia, Greece